Core Insights - iRhythm Technologies, Inc. reported significant growth and transformation in 2024, achieving a record number of Zio registrations and serving over 2 million patients [3] - The company secured FDA clearance for two 510(k) submissions related to its Zio AT device, enhancing its technology offerings [3] - iRhythm expanded its operations into four European countries and received regulatory approval in Japan, indicating a strategic move towards global growth [3] Operational Highlights - The company anticipates full-year 2024 revenue to exceed the high end of its previously stated guidance of $587.5 million [6] - A record number of new account openings for both Zio monitor and Zio AT were achieved in Q4 2024, alongside strong contributions from large national accounts [6] - iRhythm launched its first four healthcare systems on Epic Aura in Q4 2024, with a broader rollout planned for 2025 [6] Future Outlook - Revenue for the full year 2025 is expected to be approximately $675 million to $685 million, reflecting continued growth [6] - The company plans to enhance its quality systems and expand into primary care channels, focusing on population health management [3] - iRhythm aims to drive further penetration in international markets where it is still early in the commercial adoption curve [3]

Core Insights - iRhythm Technologies, Inc. is a leading digital health care company focused on creating solutions that detect, predict, and prevent disease [3] Group 1: Company Overview - iRhythm combines wearable biosensors and cloud-based data analytics with proprietary algorithms to transform data from millions of heartbeats into clinically actionable information [3] - The company's vision emphasizes delivering better data, better insights, and better health for all [3] Group 2: Upcoming Events - iRhythm will participate in the 43rd Annual J.P. Morgan Healthcare Conference, with management scheduled to present on January 13, 2025, at 4:30 p.m. Pacific Time [2] - A live and archived webcast of the presentation will be available on the company's investor website [2]

Core Viewpoint - The market is experiencing a phenomenon termed "AI fatigue," suggesting that the excitement around artificial intelligence may be waning as investors seek tangible profit-making applications of AI [1]. Group 1: AI Market Trends - The next wave of AI is expected to include interactive and autonomous AI, with companies currently making progress in these areas [3]. - Historical context shows that early investors in technology stocks like Apple and Microsoft were rewarded when the internet's potential was realized [2]. Group 2: UiPath Inc. (PATH) - UiPath specializes in robotic process automation (RPA) technology, aiming for agentic automation that integrates various agents for smarter decision-making [3]. - The company is not consistently profitable, but it has seen year-over-year revenue growth, albeit at a slowing rate [4]. - Analysts have raised price targets for PATH stock, with a consensus target of $17.71, indicating a potential upside of 21% from its recent closing price [5]. Group 3: Intuitive Surgical Inc. (ISRG) - Intuitive Surgical is a leader in robotic surgery, utilizing AI and machine learning to enhance surgical insights [6]. - The stock has increased by 61% in 2024, outperforming the broader market, despite a high forward P/E ratio exceeding 100x [7]. - Analysts are raising price targets for ISRG, with projections reaching as high as $650 per share [7]. Group 4: iRhythm Technologies Inc. (IRTC) - iRhythm designs medical devices for ambulatory cardiac monitoring, with its latest product utilizing advanced AI based on extensive heart rhythm data [8]. - The company serves 6.4 million patients in the U.S. and plans to expand its market reach, potentially increasing its total addressable market to over one billion [9]. - Despite a recent stock increase, IRTC is down 15% in 2024, but analysts maintain a consensus price target of $107.82, with some projecting targets as high as $152 [10].

Core Insights - iRhythm Technologies presented five new studies at the American Heart Association's 2024 Scientific Sessions, emphasizing its commitment to enhancing ambulatory cardiac monitoring services to improve patient outcomes and healthcare resource utilization [1][2][6] Group 1: Long-Term Continuous Monitoring (LTCM) - The studies focus on three areas: patient engagement through digital tools, evaluating arrhythmia patterns during sleep and activity, and assessing the economic impact of early arrhythmia detection in patients with type 2 diabetes and chronic obstructive pulmonary disease (COPD) [2][3] - Two studies validated the effectiveness of digital health tools in improving patient compliance with device return and highlighted the importance of patient feedback in enhancing the Zio® monitor [3][4] Group 2: Patient Engagement and Satisfaction - A study showed that using a smartphone app and text messaging significantly increased compliance rates in patients undergoing long-term continuous ambulatory cardiac monitoring, with compliance at 94.8% when both tools were used compared to 74.6% without [8] - Another study involving over 300,000 patients demonstrated that the new Zio® monitor had a 14-percentage point improvement in wear comfort compared to the previous generation device [9] Group 3: Arrhythmia Patterns - Two studies assessed the feasibility of using the Zio system to monitor arrhythmias in relation to sleep and activity, providing insights for personalized arrhythmia management [4][10] - The largest study analyzed 23,962 patients and identified distinct arrhythmia patterns associated with sleep and activity, revealing that certain arrhythmias were more likely to occur during specific states [11][12] Group 4: Economic Impact of Early Detection - A retrospective analysis indicated that early detection of arrhythmias in patients with type 2 diabetes and COPD could significantly reduce healthcare resource utilization and associated costs, with annual costs per patient being substantially higher for those with arrhythmias [13] - The study found that arrhythmia patients had more than double the hospitalization rates compared to non-arrhythmia patients, highlighting the economic burden of untreated arrhythmias [13] Group 5: iRhythm's Commitment to Evidence - iRhythm's clinical evidence program includes over 100 original research publications and insights from more than 1.5 billion hours of curated heartbeat data, reflecting its dedication to improving patient outcomes through rigorous scientific evidence [6][14]

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast of the prese ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against iRhythm Technologies, Inc. (NASDAQ: IRTC) on behalf of long-term stockholders following a class action complaint that was filed against iRhythm on February 6, 2024 with a Class Period from January 11, 2022, to May 30, 2023. Our investigation concerns whether the board of directors of iRhythm have breached their fiduciary duties to the company ...

Financial Data and Key Metrics - Revenue for Q3 2024 was $147.5 million, representing 18.4% year-over-year growth [24][48] - Gross margin for Q3 2024 was 68.8%, slightly down from Q2 2024 due to the absence of one-time favorable items [50] - Adjusted operating expenses for Q3 2024 were $143.8 million, up 14.9% sequentially and 34.3% year-over-year, primarily driven by a $32.1 million charge for technology licensing [52] - Adjusted net loss for Q3 2024 was $39.2 million, or a loss of $1.26 per share, compared to a loss of $24.1 million, or $0.79 per share, in Q3 2023 [56] - Adjusted EBITDA for Q3 2024 was negative $19.9 million, or negative 13.5% of revenue [56] Business Line Performance - Zio AT business saw accelerated momentum, with Q3 2024 being the largest quarter of Zio AT registrations ever [26] - Zio monitor demonstrated superior real-world performance compared to the legacy Zio XT device, with fewer early wear terminations, longer wear duration, and fewer patient complaints [29] - The company celebrated 1 million patients registered for the Zio monitor and 2 million registrations through EHR-integrated accounts [28][30] Market Performance - In the UK, the company achieved over 10,000 registrations in a single quarter for the first time and introduced the MyZio app to UK patients [35] - Commercial launches in Austria, the Netherlands, Switzerland, and Spain were completed in Q3 2024, marking a critical milestone in European expansion [36] - Japan received PMDA regulatory approval for Zio monitor in September 2024, with a commercial launch anticipated in 2025 [38] Company Strategy and Industry Competition - The company is undergoing a transformation to become a global growth company with a multi-sensing platform addressing multiple large end markets [11] - A technology licensing agreement with BioIntelliSense was signed to incorporate multi-sensor capabilities into future iterations of the Zio platform, aiming to expand product capabilities and enter adjacent markets like obstructive sleep apnea [39][43] - The company is focusing on FDA remediation efforts, including rebuilding the quality management system and hiring new leadership for the quality function [14][15] Management Commentary on Operating Environment and Future Outlook - Management emphasized the importance of addressing FDA regulatory issues and committed to a culture of quality and sustainability [13][17] - The company expects full-year 2024 revenue to range between $582.5 million and $587.5 million, with gross margin guidance of 68.5% to 69% [57][58] - Adjusted EBITDA margin for 2024 is expected to range from negative 2% to negative 1.5% of full-year revenues [59] Other Important Information - The company received FDA clearance for the first of two 510(k)s related to the Zio AT system and is awaiting clearance for the second submission [18][19] - The company voluntarily delayed regulatory submissions for the Zio MCT system to ensure thoroughness and completeness, with an expected filing in Q3 2025 [20][21] - The company ended Q3 2024 with approximately $522 million in unrestricted cash and short-term investments [60] Q&A Session Summary Question: Zio MCT Approval Delay - The delay in Zio MCT approval was a proactive decision by the company to bolster the submission and address FDA concerns, particularly regarding the inclusion of technicians as part of the product [66][69] - The company received FDA clearance for the second 510(k) submission for Zio AT during the call, indicating progress in remediation efforts [64][65] Question: Revenue Guidance and Q4 Confidence - The company reiterated its full-year revenue guidance, citing strong momentum in new account openings and balanced growth across Zio XT and Zio AT [71] Question: New Account Profile and Future Growth - New accounts are consistent with past wins, with a focus on large accounts and primary care channels, though the selling cycle for large accounts is longer due to EHR integration requirements [75][76] - International expansion, particularly in Europe and Japan, is expected to contribute to growth in 2025 [77] Question: BioIntelliSense Licensing Agreement - The partnership with BioIntelliSense is a long-term strategic play to enhance the Zio platform with multi-sensor capabilities, potentially enabling entry into adjacent markets like sleep apnea [82][83] Question: Remediation Efforts and MCT Improvements - The company is addressing FDA concerns by integrating technicians into the quality management system and performing additional testing for the MCT submission [89][91] - The next-generation Zio MCT will feature longer wear duration, addressing market needs [93] Question: International Expansion and Contribution - The UK market is progressing well, with a dual approach to public and private reimbursement, while new European markets are in the early stages of commercial launch [96] - Japan is expected to launch in 2025, with international revenue projected to grow to 8%-9% of total revenue over the next few years [99] Question: MCT Submission Timeline and Financial Impact - The MCT submission delay is based on incorporating FDA feedback and ensuring a robust submission, with no changes to the product design [106][107] - The delay is expected to impact 2025 revenue by approximately $10 million [104] Question: Remediation Spend and Timeline Confidence - The company is confident in its remediation timeline and spending, with a focus on rebuilding the entire quality management system and engaging external experts for periodic audits [112][113] Question: Multi-Parameter Testing Strategy - The company sees multi-parameter sensing as a way to enrich data for physicians and potentially enter adjacent markets like sleep analysis, rather than focusing solely on remote patient monitoring [129][131] Closing Remarks - The company is pleased with its operational progress and remains focused on completing FDA remediation efforts while driving growth and profitability [135]

IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -129.09%. A quarter ago, it was expected that this company would post a loss of $0.92 per share when it actually produced a loss of $0.61, delivering a surprise of 33.70%. Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 _______ ...

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510(k)-cleared enhancements will be available in 2025 SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Admini ...